Expression and/or activity of the SVCT2 ascorbate transporter may be decreased in many aggressive cancers, suggesting potential utility for sodium bicarbonate and dehydroascorbic acid in cancer therapy

This hypothesis article posits that aggressive cancers often exhibit reduced expression or activity of the SVCT2 transporter, leading to suboptimal intracellular ascorbate levels. This deficiency may result in elevated activity of hypoxia-inducible factor-1 (HIF-1), promoting tumor aggressiveness. The acidic microenvironment of tumors further impairs SVCT2 function. The author suggests that